The American Journal of Medicine
Volume 121, Issue 8 , Pages 644-646 , August 2008

Cholesteryl Ester Transfer Protein Inhibition for Coronary Heart Disease Prevention: Real Hope or Despair?

References 

  1. Gordon DJ, Probstfield JL, Garrison RG, et al. High density lipoprotein cholesterol and cardiovascular disease (Four prospective American studies). Circulation. 1989;79:8–15
  2. Badimon J, Badimon L, Fuster V. Regression of atherosclerotic lesions by high-density lipoprotein plasma traction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–1241
  3. Barter P, Gotto AM, LaRosa JC, et al. for the Treating to New Targets Investigators (HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events). N Engl J Med. 2007;357:1301–1310
  4. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target (A systematic review). JAMA. 2007;298:786–798
  5. Jiang X-C, Zhou H-W. Plasma lipid transfer proteins. Curr Opin Lipidol. 2006;17:302–308
  6. Inazu A, Brown M, Hesler C, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234–1238
  7. Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274
  8. Clark R, Ruggeri R, Cunningham D, Bamberger M. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537–552
  9. Plump A, Massuci-Magoulas L, Bruce C, et al. Increased atherosclerosis in apoE and LDL receptor knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105–1110
  10. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–207
  11. Boekholdt S, Kuivenhoven J, Wareham N, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation. 2004;110:1338–1340
  12. Klerkx A, de Grooth G, Zwinderman A, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest. 2004;34:21–28
  13. Clark R, Sutfin T, Ruggeri R, et al. Raising high density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490–497
  14. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782–1790
  15. Barter PJ, Caulfield M, Eriksson M, et al. for the ILLUMINATE Investigators (Effects of torcetrapib in patients at high risk for coronary events). N Engl J Med. 2007;357:2109–2122
  16. Nissen S, Tardiff JC, Nicholis S, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1366
  17. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630
  18. Bots ML, Visseren FL, Evans GW, et al. for the RADIANCE 2 Investigators (Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, double-blind trial). Lancet. 2007;370:153–160
  19. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356:1364–1366
  20. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol. 2007;18:157–163
  21. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipo-protein. Curr Opin Lipidol. 2007;18:427–434
  22. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in health individuals: two double-blind, randomized placebo-controlled phase 1 studies. Lancet. 2007;370:1907–1914
  23. Frishman WH. A historical perspective on the development of β-adrenergic blockers. J Clin Hypertens. 2007;9(4 Suppl 3):19–27

PII: S0002-9343(08)00299-4

doi: 10.1016/j.amjmed.2008.02.040

The American Journal of Medicine
Volume 121, Issue 8 , Pages 644-646 , August 2008

Article Tools